Transitional ePRO Diary Liver
Launched by FROM- FONDAZIONE PER LA RICERCA OSPEDALE DI BERGAMO- ETS · Mar 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Transitional EPRO Diary Liver, is part of a larger project aimed at helping patients with liver disease manage their condition more effectively using a digital tool. The main goal of the study is to understand how young patients, aged 14 to 20, transition from pediatric care to adult care after receiving a liver transplant. By gathering information about their experiences, the researchers hope to identify factors that can help improve their psychological well-being during this important change.
Eligible participants are young people who have either received a liver transplant or are waiting for one at a specific transplant center. They should also have used certain mobile apps recently and provide signed consent to join the study. Participants can expect to share their experiences and provide information about their health, which will aid in developing better support tools for both patients and their healthcare teams. It's important to note that while this digital tool will enhance patient care, it is not a replacement for regular medical visits and treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients between the ages of 14 and 20 who have been transplanted at the ASST-PG23 transplant center or are awaiting a liver transplant and belong to the transition to adult services
- • signed informed consent
- • proven use of the APPs (to be assessed based on the last 2 weeks)
- Exclusion Criteria:
- • -
About From Fondazione Per La Ricerca Ospedale Di Bergamo Ets
Fondazione per la Ricerca Ospedale di Bergamo ETS is a leading clinical research organization dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. Based in Bergamo, Italy, the foundation collaborates with healthcare professionals, academic institutions, and industry partners to design and conduct high-quality clinical trials across various therapeutic areas. With a strong emphasis on ethical standards and patient safety, the foundation aims to facilitate the translation of scientific discoveries into effective treatments, thereby contributing to the enhancement of healthcare practices and the well-being of the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergamo, Milano, Italy
Patients applied
Trial Officials
Stefano Fagiuoli, MD
Principal Investigator
ASST-PG23
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported